D-Pharm treats first stoke patient in Phase III trial

The company is recruiting about 770 patients altogether.

Biotech firm D-Pharm Ltd. (TASE: DPRM) has begun treating the first patient in the Phase III trial of its DP-b99 drug to treat strokes. The patient is at Wolfson Medical Center in Holon.

The company is recruiting about 770 patients altogether. The study will be conducted at 100 medical centers around the world - in Israel, as well as in the US, Canada, Germany, France, Italy, and other European countries.

The trial will study the effect on ischemic stroke victims, treated with 1 mg/kg/day of DP-b99 for 4 consecutive days. The results will be compared with those of a group receiving a placebo.

D-Pharm was established in 1993 by Dr. Alex Kozak. The Rehovot-based company designs and develops innovative drugs for the treatment of brain disorders and trauma.

Shares in D-Pharm are down 1% in late-morning trading.

Published by Globes [online], Israel business news - www.globes-online.com - on December 31, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018